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Effect of smoking status on lung function,
patient-reported outcomes, and safety
among COPD patients treated with
glycopyrrolate inhalation powder: pooled
analysis of GEM1 and GEM2 studies
Donald P. Tashkin1*, Thomas Goodin2, Alyssa Bowling2, Barry Price2, Ayca Ozol-Godfrey2, Sanjay Sharma2 and
Shahin Sanjar2
Abstract
Background: Smoking is a major risk factor for COPD and may impact the efficacy of COPD treatments; however, a
large proportion of COPD patients continue to smoke following diagnosis.
Methods: This post-hoc analysis of pooled data from the replicate 12-week, placebo-controlled GEM1 and GEM2
studies assessed the impact of smoking status on the efficacy and safety of glycopyrrolate 15.6 μg twice daily vs
placebo in patients with moderate-to-severe COPD. Data from 867 patients enrolled in GEM1 and GEM2 were
pooled for analysis and grouped by smoking status (57% current smokers, 43% ex-smokers). Forced expiratory
volume in 1 s (FEV1) area under the curve from 0 to 12 h, trough FEV1, forced vital capacity, St George’s Respiratory
Questionnaire (SGRQ) total score, COPD assessment test (CAT) score, transition dyspnea index (TDI) focal score, daily
symptom scores, and rescue medication use were assessed in current smokers and ex-smokers. Incidences of
adverse events (AEs) and serious AEs (SAEs) were also assessed.
Results: Treatment with glycopyrrolate resulted in significant improvements in all lung function measures,
independent of smoking status. In both current and ex-smokers, changes from baseline in trough FEV1 were less
marked in patients taking inhaled corticosteroids (ICS) than those not receiving ICS. Changes from baseline in SGRQ
total score and rescue medication use were significantly greater with glycopyrrolate compared with placebo,
regardless of smoking status. Changes in the CAT score, TDI focal score, and daily symptom scores significantly
improved versus placebo, but only in current smokers. Improvements in patient-reported outcomes (PROs) with
glycopyrrolate relative to placebo were numerically greater in current smokers than ex-smokers. The incidences of
AEs and SAEs were similar regardless of smoking status.
Conclusions: In this post-hoc analysis of GEM1 and GEM2, glycopyrrolate use led to significant improvements in
lung function, independent of baseline smoking status; improvements were less marked among patients receiving
background ICS, regardless of baseline smoking status. Improvements in PROs were greater with glycopyrrolate
than placebo, and the magnitude of changes was numerically greater among current smokers. The safety profile of
glycopyrrolate was comparable between current smokers and ex-smokers.
Keywords: Bronchodilator, COPD, Glycopyrrolate, LAMA, Lung function, Patient-reported outcomes, Safety, Smoking status
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: dtashkin@mednet.ucla.edu
1David Geffen School of Medicine, University of California at Los Angeles, Los
Angeles, CA, USA
Full list of author information is available at the end of the article
Tashkin et al. Respiratory Research          (2019) 20:135 
https://doi.org/10.1186/s12931-019-1112-0
Background
Tobacco smoking is well established as a major risk
factor for the development of chronic obstructive
pulmonary disease (COPD) [1–4]. A Swedish cohort
study reported that approximately 50% of smokers
eventually develop COPD [5], and according to
World Health Organization data in 2012, 42% of all
COPD-related deaths were attributable to tobacco
smoking [6]. Unfortunately, approximately 40% of
patients continue to smoke following diagnosis of
COPD [7]. Smoking has been shown to reduce the
efficacy of inhaled corticosteroids (ICS) in patients
with asthma [8, 9] and leads to faster decline of lung
function among patients with COPD treated with
bronchodilator/ICS combinations [10, 11]. Smoking
affects the exposure and efficacy of ICS by disrupt-
ing the histone deacetylase 2 enzyme system, in-
creasing production of inflammatory cytokines, and
activating the p38 MAPK pathway [12].
Glycopyrrolate inhalation powder (GLY; SEEBRI®
NEOHALER®, Sunovion Pharmaceuticals Inc.) is a long-
acting muscarinic antagonist (LAMA) approved by the
US Food and Drug Administration at a dose of 15.6 μg
twice daily (BID) for the long-term maintenance treat-
ment of airflow obstruction in patients with COPD [13].
Two replicate, 12-week Phase III studies, Glycopyrrolate
Effect on syMptoms and lung function 1 and 2 (GEM1
and GEM2), demonstrated the efficacy and safety of
GLY vs placebo in patients with moderate-to-severe
COPD and a smoking history of ≥10 pack-years [14, 15].
The proportions of current smokers were 61% in GEM1
and 53% in GEM2. Treatment with GLY resulted in sig-
nificantly improved lung function, as assessed by forced
expiratory volume in 1 s (FEV1) area under the curve
from 0 to 12 h (AUC0–12h) and trough FEV1, as well as
patient-reported outcomes (PROs) [14, 15] compared
with placebo. GLY was well-tolerated in both studies,
with safety outcomes similar to placebo. In the primary
analysis of the GEM1 and GEM2 studies, it was shown
that the primary endpoint, FEV1 AUC0–12h was im-
proved to a similar extent in both current and ex-
smokers [14, 15].
Given the significant proportion of COPD patients
who smoke, and the potential for treatment efficacy
to be impaired among current smokers, evaluation of
the impact of smoking status on bronchodilator effi-
cacy and safety may help to inform clinical decision-
making [8]. While the primary analyses of the 2 stud-
ies briefly assessed the impact of smoking status on
the primary endpoint, in this post-hoc analysis of
pooled data from GEM1 and GEM2, we evaluated the
impact of patients’ baseline smoking status on all effi-
cacy and safety responses to GLY compared to pla-
cebo over 12 weeks.
Methods
Study design
The study designs of GEM1 (NCT01709864) and GEM2
(NCT01715298) have been published previously [14, 15].
Briefly, GEM1 and GEM2 were replicate, multicenter,
double-blind, placebo-controlled studies that evaluated
the efficacy and safety of GLY in patients with
moderate-to-severe COPD (Additional file 1: Figure S1).
Patients were randomized 1:1 to receive either GLY
15.6 μg BID or placebo delivered via the NEOHALER®
device for 12 weeks; randomization was stratified ac-
cording to baseline smoking status (current or ex-
smoker). Ex-smokers were defined as patients who had
not smoked for ≥6 months at screening. Patients’ smok-
ing history and status, including pack-years (calculated
as number of packs/day multiplied by the number of
years of smoking) and date of quitting for ex-smokers,
were reported using a questionnaire; smoking history
was assessed at screening (pre-dose) only, while current
smoking status was assessed at randomization and week
12 or at treatment discontinuation. Background ICS at
stable doses and albuterol (as rescue medication) were
permitted throughout the studies.
Patients
Eligibility criteria have been published previously [14,
15]. Briefly, enrolled patients included males or females
≥40 years of age with stable, symptomatic COPD (Global
Initiative for Chronic Obstructive Lung Disease [GOLD]
2011, stages 2 and 3) [16]. Patients were current or ex-
smokers with ≥10 pack-year smoking history and had
qualifying post-bronchodilator FEV1 (1 h after inhalation
of ipratropium bromide 84 μg) ≥30% and < 80% of pre-
dicted normal, a FEV1/forced vital capacity (FVC) ratio <
0.70, and modified Medical Research Council grade ≥ 2
at the run-in visit. Patients were asked to refrain from
smoking one hour before scheduled clinic visits and
spirometry testing.
Post-hoc analysis
Data from the GEM1 and GEM2 studies were pooled to
compare the effect of baseline smoking status in patients
receiving GLY or placebo. Evaluated endpoints included
lung function (assessed by changes from baseline in
FEV1 AUC0-12h, trough FEV1, and FVC at Week 12) and
PROs (measured by changes from baseline in St George’s
Respiratory Questionnaire [SGRQ] total score, COPD
Assessment Test [CAT™] score, and transition dyspnea
index [TDI] focal score at Week 12). Changes from
baseline over 12 weeks in symptom burden and rescue
medication use were assessed using data from patient
diaries. Safety assessments included incidence of adverse
events (AEs), serious AEs (SAEs), and serious cerebro-
and cardio-vascular (CCV) AEs. Trough FEV1 was
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further analyzed based on the presence/absence of back-
ground ICS use.
Statistical analyses
The full analysis set was used for all efficacy outcomes
and included all randomized patients who received at
least one dose of treatment. Changes from baseline in
FEV1 AUC0-12h, trough FEV1, and FVC at Week 12 were
analyzed using a mixed-model for repeated measures.
Changes from baseline in SGRQ total score, CAT score,
symptom scores, and rescue medication use over 12
weeks, and overall changes in TDI focal score at Week
12 were analyzed using a linear mixed model. The pro-
portions of patients achieving the thresholds for minimal
clinically important differences (reduction in SGRQ total
score ≥ 4 units [17] and change in TDI focal score ≥ 1
[18]) were analyzed using a logistic regression model
with the same terms as the linear mixed model. All
models included covariates for baseline smoking status
(current smoker or ex-smoker) and baseline ICS use
(yes/no). Reduction in CAT score ≥ 2 [19] was also
assessed by smoking status. No multiplicity adjustments
were made for the post-hoc multiple comparisons.
The safety set included all patients who received at
least one dose of treatment, and was used for analysis of
all safety variables. Safety data were analyzed by smoking
status using descriptive statistics. AEs were coded ac-
cording to Medical Dictionary for Regulatory Activities
version 17.0. All statistical procedures were performed
using SAS® version 9.2 or higher (SAS Institute Inc.,
Cary, NC).
Results
Patient demographics and baseline characteristics
Data from 867 patients enrolled in GEM1 and GEM2
were pooled for analysis. Of these patients, 496 (57.2%)
were current smokers and 371 (42.8%) were ex-smokers
at the time of randomization (Table 1); less than 4% of
patients had a change in smoking status during the 12-
week trial. Patient demographics and disease characteris-
tics at baseline were generally comparable between the
current and ex-smoker subgroups. Ex-smokers were
older (67.0 vs 60.0 years), had a longer duration of dis-
ease (6.0 vs 4.8 years), and higher rates of background
ICS use (35.0% vs 24.6%) compared with current
smokers. For both subgroups, there were more males
(current smokers 59.1%; ex-smoker 56.9%) than females,
and most patients were Caucasian (current smoker
86.7%; ex-smoker 91.1%). A greater proportion of
current smokers were classified as GOLD 2 (current
smoker 66.7%; ex-smoker 57.4%) vs GOLD 3 (current
smoker 31.9%; ex-smoker 41.2%), and GOLD group B
(current smoker 64.1%; ex-smoker 54.4%) vs group D
(current smoker 34.5%; ex-smoker 43.9%).
Efficacy
Changes from baseline in lung function
The improvement from baseline in FEV1 AUC0–12h at
12 weeks with GLY was significant for both current
smokers and ex-smokers (Fig. 1a); the placebo-adjusted
improvement among patients treated with GLY was nu-
merically greater among ex-smokers compared with
current smokers. Similarly, there were significant im-
provements in trough FEV1 at Week 12 among patients
treated with GLY compared with those receiving pla-
cebo, in both current and ex-smokers (Fig. 1b); the
placebo-adjusted change was numerically greater in ex-
smokers treated with GLY than in current smokers. In
patients who did not receive background ICS, significant
changes in trough FEV1 with GLY versus placebo oc-
curred in both current and ex-smokers (Fig. 1c). How-
ever, in patients who received background ICS,
improvements in trough FEV1 were significantly greater
for GLY versus placebo in ex-smokers but not current
smokers (Fig. 1c); this may be due to the marked differ-
ences in response observed with placebo between the
smoking subgroups. Consistent with the overall im-
provements in trough FEV1, the placebo-adjusted change
in trough FEV1 with GLY was numerically greater in ex-
smokers than current smokers, whether or not patients
had received background ICS.
The improvement from baseline in trough FVC with
GLY was also significant in both current smokers and ex-
smokers (Fig. 1d) compared with placebo; of note, FVC
values were similar between current and ex-smokers and
across treatment groups at baseline (Table 1). While there
was no significant difference in the change from baseline
in trough FVC with GLY between current and ex-
smokers, the improvement among patients receiving pla-
cebo was significantly greater in current smokers than ex-
smokers. Consequently, the magnitude of the placebo-
adjusted improvement with GLY was larger in ex-smokers
than current smokers (Fig. 1d).
Change from baseline in SGRQ total scores and CAT scores
The change from baseline in SGRQ total score at Week
12 was significantly greater for patients treated with
GLY than those receiving placebo, regardless of their
smoking status at baseline (Fig. 2a); improvements with
GLY among current smokers exceeded the minimal clin-
ically important difference (MCID; 4 units [17]) and
were considered clinically significant. The placebo-
adjusted improvement from baseline in SGRQ total
score was numerically greater in current smokers than
ex-smokers; this may be attributed, at least in part, to
the improvement with placebo being greater in ex-
smokers than in current smokers. Consistent with the
numerically greater improvement in SGRQ total score in
current smokers, odds of a current smoker being an
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SGRQ responder (≥4-unit reduction in total SGRQ
score) were significantly greater for GLY than for pla-
cebo (odds ratio [OR]: 1.69, 95% confidence interval
[CI]: 1.15, 2.48; P < 0.01); this was not the case for an
ex-smoker (OR: 1.46, 95% CI: 0.94, 2.27; P = 0.089).
At Week 12, treatment with GLY was associated with
a significant reduction from baseline in CAT score ver-
sus placebo in current but not ex-smokers (Fig. 2b).
There was a significant difference between smokers and
ex-smokers in the change from baseline in CAT score
with placebo; this may have contributed to the treatment
difference being smaller in ex-smokers than current
smokers. Consistently, in the GLY treatment arm, the
proportion of current smokers with a clinically import-
ant reduction in CAT score (≥2) at Week 12 (52.2%) was
greater than the proportion of ex-smokers (44.1%); the
Table 1 Patient demographics and disease characteristics at baseline
Current smoker Ex-smoker
GLY (n = 251) Placebo (n = 245) Total (N = 496) GLY (n = 186) Placebo (n = 185) Total (N = 371)
Age, years, median (range) 61.0 (44, 83) 60.0 (41, 84) 60.0 (41, 84) 68.0 (43, 86) 67.0 (48, 87) 67.0 (43, 87)
Male, n (%) 142 (56.6) 151 (61.6) 293 (59.1) 109 (58.6) 102 (55.1) 211 (56.9)
Race, n (%)
Caucasian 223 (88.8) 207 (84.5) 430 (86.7) 172 (92.5) 166 (89.7) 338 (91.1)
Black 22 (8.8) 35 (14.3) 57 (11.5) 8 (4.3) 11 (5.9) 19 (5.1)
Asian 1 (0.4) 0 1 (0.2) 2 (1.1) 3 (1.6) 5 (1.3)
Native American 2 (0.8) 2 (0.8) 4 (0.8) 0 2 (1.1) 2 (0.5)
Other 3 (1.2) 1 (0.4) 4 (0.8) 4 (2.2) 3 (1.6) 7 (1.9)
Duration of COPD, years, median (range) 4.7 (0.0, 19.0) 4.9 (0.0, 29.9) 4.8 (0.0, 29.9) 6.1 (0.0, 28.6) 6.0 (0.0, 32.6) 6.0 (0.0, 32.6)
Airflow obstruction (GOLD 2011 [16]), n (%)
Mild (GOLD 1) 0 1 (0.4) 1 (0.2) 0 0 0
Moderate (GOLD 2) 166 (66.1) 165 (67.3) 331 (66.7) 111 (59.7) 102 (55.1) 213 (57.4)
Severe (GOLD 3) 83 (33.1) 75 (30.6) 158 (31.9) 72 (38.7) 81 (43.8) 153 (41.2)
Missing 2 (0.8) 4 (1.6) 6 (1.2) 3 (1.6) 2 (1.1) 5 (1.3)
Combined assessment of COPD (GOLD 2011 [16]), n (%)
Group A 1 (0.4) 0 1 (0.2) 0 1 (0.5) 1 (0.3)
Group B 161 (64.1) 157 (64.1) 318 (64.1) 108 (58.1) 94 (50.8) 202 (54.4)
Group C 0 0 0 0 0 0
Group D 87 (34.7) 84 (34.3) 171 (34.5) 75 (40.3) 88 (47.6) 163 (43.9)
Missing 2 (0.8) 4 (1.6) 6 (1.2) 3 (1.6) 2 (1.1) 5 (1.3)
Estimated number of pack-years, median
(range)
46.0 (10.0,
146.5)
48.0 (11.0, 184.0) 47.0 (10.0,
184.0)
46.0 (12.5,
240.0)
49.0 (10.0, 156.0) 47.0 (10.0,
240.0)
ICS use at baseline, n (%) 56 (22.3) 66 (26.9) 122 (24.6) 65 (34.9) 65 (35.1) 130 (35.0)
Pre-bronchodilator FEV1, mean (SD)
Volume, L 1.3 (0.5) 1.4 (0.5) 1.4 (0.5) 1.3 (0.4) 1.2 (0.5) 1.2 (0.5)
% predicted 46.7 (12.8) 47.3 (12.9) 47.0 (12.8) 45.9 (12.8) 44.9 (13.5) 45.4 (13.2)
Post-bronchodilator FEV1, mean (SD)
Volume, L 1.6 (0.5) 1.6 (0.5) 1.6 (0.5) 1.5 (0.5) 1.4 (0.5) 1.4 (0.5)
% predicted 55.5 (12.9) 56.3 (12.7) 55.9 (12.8) 53.2 (13.5) 52.7 (13.6) 53.0 (13.5)
FVC, L, mean (SD)
Pre-bronchodilator 2.6 (0.9) 2.7 (0.9) 2.7 (0.9) 2.6 (0.8) 2.5 (0.8) 2.6 (0.8)
Post-bronchodilator 3.1 (0.9) 3.1 (0.9) 3.1 (0.9) 2.9 (0.9) 2.9 (0.9) 2.9 (0.9)
FEV1/FVC, %
Pre-bronchodilator 50.9 (10.2) 50.8 (9.9) 50.8 (10.0) 48.9 (11.0) 47.1 (10.7) 48.0 (10.8)
Post-bronchodilator 52.2 (10.2) 52.3 (9.8) 52.2 (10.0) 50.4 (11.1) 49.1 (10.8) 49.8 (10.9)
COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung
Disease, GLY glycopyrrolate, ICS inhaled corticosteroid, SD standard deviation
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proportions for the placebo arm were 34.2 and 42.6%,
respectively.
Changes in TDI focal score
For TDI focal score, the treatment difference was signifi-
cant in current smokers, but not ex-smokers (Fig. 3).
Placebo-adjusted improvements in TDI focal score were
numerically greater among current smokers compared
with ex-smokers, although the differences were not sig-
nificant. The odds of achieving the MCID (≥1 [18]) were
greater for GLY than placebo in both current smokers
(OR: 1.82, 95% CI: 1.23, 2.70; P < 0.01) and ex-smokers
(OR: 1.67, 95% CI: 1.06, 2.65; P < 0.05).
Changes from baseline in symptom scores
Over 12 weeks, treatment with GLY led to significant de-
creases in LS mean daily total symptom score compared
with placebo among current smokers but not ex-
smokers (Table 2). Similar results were observed for
mean daytime and nighttime symptom score (Table 2).
For all symptom-related PROs, the magnitude of im-
provement with GLY was greater in current smokers
than ex-smokers.
Changes from baseline in rescue medication use
Treatment with GLY led to significantly greater reduc-
tions in mean daily rescue medication use compared
a b
c d
Fig. 1 Pooled analysis of a FEV1 AUC0–12h, b trough FEV1, c trough FEV1 by baseline ICS use, and d FVC at Week 12 by smoking status (FAS).
**P < 0.01, ***P < 0.001 vs placebo; †P < 0.05, ††P < 0.01 vs ex-smoker. AUC0-12h, area under the curve 0–12 h; FAS, full analysis set; FEV1, forced
expiratory volume in 1 s; FVC, forced vital capacity; GLY, glycopyrrolate; ICS, inhaled corticosteroids; LSM, least squares mean; SE standard error
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with placebo, in both current smokers and ex-smokers
(Fig. 4a). GLY had a similar effect on both daytime and
nighttime rescue medication use, in both current and ex-
smokers (Fig. 4b-c). Overall, the magnitude of improve-
ment in rescue medication use with GLY was greater in
current than ex-smokers. The mean percentage of days
with no rescue medication use was higher for GLY than
placebo in both current and ex-smokers (Fig. 4d), but
there were no significant differences between current
smokers and ex-smokers in either treatment group.
Safety
The overall incidence of AEs was generally similar be-
tween the treatment groups over 12 weeks, irrespective of
smoking status, with the lowest incidence being among
current smokers receiving placebo (39.6%) and the highest
among ex-smokers receiving GLY (48.4%; Table 3).
The most common AE, occurring to a similar extent
in both treatment arms and in current and ex-smokers,
was worsening of COPD (Table 3). The incidence of
cough was similar between treatments but was lower in
current smokers than ex-smokers (current smokers:
GLY, 2.0%, placebo: 1.6%; ex-smokers: GLY, 4.3%, pla-
cebo: 3.8%). The incidence of upper respiratory tract in-
fections was similar among current smokers regardless
of treatment (smokers: GLY, 2.4%, placebo: 2.5%), but in
ex-smokers was greater with GLY (4.8%) than placebo
(1.6%). In current smokers, the proportion of patients
with at least one SAE was similar for GLY and placebo
(4.4% vs 4.9%, respectively); in ex-smokers, the propor-
tion was slightly higher for GLY than for placebo (4.8%
vs 2.7%, respectively).
In current smokers, the incidence of serious CCV AEs
was lower for GLY than for placebo (1 [0.4%] vs 5
[2.0%], respectively). There were no major adverse car-
diac events (MACEs) in the GLY arm, versus 4 (1.6%)
events in the placebo arm, including two cases of coron-
ary revascularization and one each of non-fatal myocar-
dial infarction (MI), non-fatal stroke, and heart failure
requiring hospitalization. In ex-smokers, the incidences
of serious CCV AEs (5 [2.7%] vs 1 [0.5%]) and MACE (3
[1.6%] vs 1 [0.5%]) were greater for GLY than for pla-
cebo. Among ex-smokers, MACE included three cases
of non-fatal MI in the GLY arm, and one coronary revas-
cularization in a patient taking placebo.
Discussion
Smoking status is known to impact the efficacy of ICS
treatment in asthma [8, 9] and leads to faster decline in
patients with COPD [10, 11]. However, studies of the
LAMA tiotropium [20, 21] showed non-significant long-
term differences in bronchodilator response between
current and ex-smokers. The results of this pooled ana-
lysis of data from the GEM1 and GEM2 studies showed
that baseline smoking status did not have a significant
impact on the efficacy or safety profile of GLY.
The magnitude of the effect of GLY (relative to pla-
cebo) on FEV1 AUC0-12h, trough FEV1, and trough FVC
at 12 weeks was greater in ex-smokers than current
smokers, but none of the differences between current
a
b
Fig. 2 Pooled analysis of a SGRQ total score and b CAT score at
Week 12 by smoking status (FAS). *P < 0.05, ***P < 0.001 vs placebo;
†P < 0.05 vs smoker. CAT, COPD Assessment Test; FAS, full analysis
set; GLY, glycopyrrolate; LSM, least squares mean; SE, standard error;
SGRQ, St George’s Respiratory Questionnaire
Fig. 3 Pooled analysis of TDI focal score at Week 12 by smoking status
(FAS). **P < 0.01 vs placebo. FAS, full analysis set; GLY, glycopyrrolate;
LSM, least squares mean; SE, standard error; TDI, transition dyspnea index
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Table 2 Least squares mean (standard error) change from baseline in symptom scores
Current smoker Ex-smoker
Parameter GLY Placebo Δ P value GLY Placebo Δ P value
Mean total symptom score
Daily −1.3 (0.1) −0.8 (0.1) −0.5 (0.1) < 0.001 −1.1 (0.1) − 1.0 (0.1) −0.1 (0.1) 0.616
Daytime −1.1 (0.1) − 0.5 (0.1) − 0.6 (0.1) < 0.001 − 0.9 (0.1) − 0.8 (0.1) − 0.1 (0.2) 0.746
Nighttime − 1.2 (0.1) − 0.8 (0.1) − 0.5 (0.1) < 0.01 −1.0 (0.1) − 1.0 (0.1) 0.0 (0.2) 0.841
Mean daily cough scores − 0.3 (0.02) − 0.2 (0.02) − 0.1 (0.03) < 0.05 − 0.2 (0.03) −0.3 (0.03) 0.1 (0.04) 0.179
Mean daily sputum production scores −0.2 (0.02) −0.1 (0.02) − 0.1 (0.03) < 0.01 − 0.2 (0.03) −0.2 (0.03) 0.01 (0.04) 0.884
% nights with no nighttime awakening 13.7 (1.6) 7.6 (1.6) 6.1 (2.2) < 0.01 11.8 (1.9) 13.6 (1.9) −1.8 (2.5) 0.484
% days with no daytime symptoms 4.5 (1.2) 2.1 (1.2) 2.4 (1.5) 0.105 4.5 (1.4) 3.0 (1.3) 1.6 (1.7) 0.367
% days able to perform daily activities 6.0 (1.7) −1.6 (1.7) 7.6 (2.3) < 0.001 7.3 (1.9) 4.4 (1.9) 2.9 (2.6) 0.277
GLY glycopyrrolate, Δ treatment difference
a b
c d
Fig. 4 Pooled analysis of mean a daily, b daytime, and c nighttime number of rescue medication puffs, and d percentage of days with no rescue
medication use over 12 weeks by smoking status (FAS). *P < 0.05, ***P < 0.001 vs placebo. FAS, full analysis set; GLY, glycopyrrolate; LSM, least
squares mean; SE, standard error
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and ex-smokers were significant. The effects of GLY
were not impacted by baseline ICS use, while the impact
on PROs was numerically but not significantly greater in
current than ex-smokers. Conversely, in patients receiv-
ing tiotropium for 12 weeks there were numerical but
not statistical improvements in FEV1 in current vs ex-
smokers [20]. However, in the same study among
current smokers, baseline airflow obstruction was less
severe in the tiotropium arm than the placebo arm,
whereas for ex-smokers the opposite was true. This may
have accounted for the apparently greater response to
tiotropium in current smokers, consistent with observa-
tions that bronchodilator responsiveness appears to be
related to the degree of airflow obstruction, with patients
having moderate obstruction showing greater responses
to bronchodilators than those with severe obstruction by
FEV1 criteria [22]. In contrast, in the current study,
baseline lung function was similar between treatment
arms and between current and ex-smokers. This may ac-
count for the slight difference in outcomes with regard
to current versus ex-smokers. In the 4-year UPLIFT
trial, tiotropium treatment led to greater improvement
in lung function in continuing current smokers than in
ex-smokers. However, these results may also have been
confounded by the fact that baseline airflow obstruction
was greater in ex-smokers than current smokers, and
concomitant treatment with long-acting β2-agonists, ICS
and methylxanthines was permitted throughout the trial
[21]. Importantly, in the current analysis, improvement
in lung function outcomes with placebo were greater in
current smokers than ex-smokers; this may have influ-
enced the differences in placebo-adjusted outcomes be-
tween current and ex-smokers.
The GOLD 2019 report recommended the addition of
ICS to long-acting bronchodilator therapies in patients
with more severe disease experiencing dyspnea or
exacerbations and having high eosinophil counts [1].
Consistent with the observation that smoking can im-
pact ICS efficacy and disease progression during treat-
ment of patients with asthma and COPD [8–11, 23–25],
in this analysis, current smokers receiving background
ICS had non-significant improvement in trough FEV1
with GLY compared with placebo, whereas ex-smokers
had a significant improvement, regardless of background
ICS use; however, this was, at least in part, due to differ-
ences in lung function improvement in the placebo arm
between current and ex-smokers. Provided they were
not receiving background ICS, both current and ex-
smokers had significant improvements in trough FEV1.
The most notable differences between current and ex-
smokers were related to changes in PROs. While SGRQ
total scores and rescue medication use were significantly
improved with GLY compared with placebo in both
current and ex-smokers, numerically greater improve-
ments in placebo-adjusted SGRQ total score among
current smokers compared to ex-smokers receiving GLY
may be attributed, in part, to the greater improvements
among ex-smokers receiving placebo. In contrast,
placebo-adjusted changes from baseline in CAT and
symptoms scores, as well as changes in TDI focal scores
at Week 12, were significantly improved only in current
smokers, but not in ex-smokers. While the differences in
CAT scores between current and ex-smokers may be
due to greater improvements among ex-smokers com-
pared with smokers receiving placebo, similar differences
between current and ex-smokers in placebo effects were
not observed in TDI focal scores. Previous studies of tio-
tropium showed similar significant placebo-adjusted
changes from baseline in SGRQ total score irrespective
of smoking status, although numerically greater im-
provements were observed among current smokers
compared with ex-smokers [20, 21].
Table 3 Adverse events reported by ≥2% of patients in either treatment group (safety set)
Preferred term Current smoker Ex-smoker
GLY (n = 252) Placebo (n = 245) GLY (n = 186) Placebo (n = 185)
Patients experiencing ≥1 AE 116 (46.0) 97 (39.6) 90 (48.4) 83 (44.9)
COPD worsening/exacerbation 37 (14.7) 40 (16.3) 31 (16.7) 35 (18.9)
Cough 5 (2.0) 4 (1.6) 8 (4.3) 7 (3.8)
Upper respiratory tract infection 6 (2.4) 6 (2.5) 9 (4.8) 3 (1.6)
Nasopharyngitis 3 (1.2) 4 (1.6) 5 (2.7) 5 (2.7)
Headache 8 (3.2) 6 (2.5) 2 (1.1) 7 (3.8)
Oropharyngeal pain 3 (1.2) 2 (0.8) 6 (3.2) 3 (1.6)
Nasal congestion 2 (0.8) 4 (1.6) 2 (1.1) 5 (2.7)
Dyspnea 2 (0.8) 1 (0.4) 1 (0.5) 4 (2.2)
Bronchitis 2 (0.8) 1 (0.4) 1 (0.5) 5 (2.7)
Gastroenteritis viral 1 (0.4) 5 (2.0) 1 (0.5) 0
AE adverse event, COPD chronic obstructive pulmonary disease, GLY glycopyrrolate
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The differences observed in PROs between current
and ex-smokers in this analysis may have been influ-
enced by disease severity at baseline, with patients with
more severe disease having possibly ceased smoking due
to worse baseline lung function. This is supported by
baseline characteristics showing that more ex-smokers
than current smokers had longer disease duration and
were classified as GOLD 3 and GOLD group D. Another
potential explanation for the greater improvements in
PROs in current smokers than ex-smokers is improve-
ments in symptoms directly driven by active smoking,
such as increased mucus secretion; such improvements
in symptoms directly caused by active smoking may have
led to greater positive outcomes among current smokers.
In addition, the central actions of nicotine in the brain,
which include release of neurotransmitters such as dopa-
mine [26], may have a positive impact on patients’ per-
ceptions of quality of life.
The safety profile of GLY was not substantially im-
pacted by smoking status at baseline, although there
were differences in the incidences of COPD worsening,
cough, and upper respiratory tract infections between
current and ex-smokers and treatment arms; these may
be due to differences in baseline characteristics (e.g. dis-
ease severity) between subgroups. AEs of special interest
associated with anticholinergic therapies (e.g. dry mouth
and dizziness) were infrequent and were similar between
treatments. Overall, the AE profile of GLY was not af-
fected by smoking status at baseline. Although CCV AEs
and MACE were most frequent in ex-smokers, the inci-
dences were low and similar to those reported for other
LAMAs [27, 28].
The main limitation of this analysis is that post-hoc
comparisons were not adjusted for multiplicity. Only a
small number of patients stopped or started smoking
during the GEM1 and GEM2 studies, which did not im-
pact the observed outcomes. Additional prospective
studies are needed to better understand the impact of
smoking status on clinical outcomes with different bron-
chodilators available for the treatment of patients with
COPD.
Conclusions
In this post-hoc analysis of pooled data from the GEM1
and GEM2 studies, GLY treatment led to significant im-
provements in lung function, SGRQ total score, and res-
cue medication use vs placebo in both smokers and ex-
smokers. Current smokers receiving background ICS
therapy on top of GLY had non-significant improve-
ments in trough FEV1 compared with placebo; this is
consistent with previous studies that demonstrated ef-
fects of smoking on ICS efficacy. GLY treatment resulted
in clinically important improvements in CAT scores,
TDI focal scores, and daily symptom scores in both
current and ex-smokers, with significant improvements
over placebo only among current smokers. These data
support the use of GLY 15.6 μg BID in patients with
moderate-to-severe COPD regardless of their baseline
smoking status, although the magnitude of benefit may
differ between current and ex-smokers.
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